BeOne Medicines Drug Pipeline

BeOne Medicines maintains a substantial clinical development portfolio, with 36 registered trials since 2008, of which 35 are currently active. The pipeline spans early- to late-stage development, comprising 22 Phase 1, 6 Phase 2, and 11 Phase 3 trials. The company's therapeutic focus is heavily concentrated in Oncology, which accounts for all active programs. Within Oncology, the portfolio targets a range of indications, with a notable emphasis on Solid Tumor (Advanced), Chronic Lymphocytic Leukemia (CLL), and Non-Hodgkin Lymphoma. The CLL program includes six Phase 3 trials, while Solid Tumor (Advanced) has 14 active trials, none of which are in Phase 3. Other Oncology indications with active trials include Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer. The significant number of Phase 3 trials in CLL suggests a potential near-term focus on bringing new therapies to market in this specific area of Oncology.